Methods and formulations for transdermal or transmucosal application of active agents
First Claim
Patent Images
1. A formulation for the transdermal or transmucosal administration of an active agent comprising:
- at least one active agent, provided that the active agent is not testosterone alone, and that when the active agent is an estrogen or progestin, a therapeutically effective amount of a progestin or estrogen, respectively, is not present in the formulation; and
a delivery vehicle comprising an alkanol, a polyalcohol and a permeation enhancer in an amount sufficient to provide permeation enhancement of the active agent through mammalian dermal or mucosal surfaces;
wherein the formulation is substantially free of long-chain fatty alcohols, long-chain fatty acids and long-chain fatty esters to avoid undesirable odor and irritation from such compounds during use of the formulation.
3 Assignments
0 Petitions
Accused Products
Abstract
Methods, formulations, and kits for providing transdermal or transmucosal delivery of active agents to subjects in need thereof. The formulations and methods treat symptoms of hormonal disorders including hypogonadism, female sexual desire disorder, female menopausal disorder, and adrenal insufficiency.
275 Citations
59 Claims
-
1. A formulation for the transdermal or transmucosal administration of an active agent comprising:
-
at least one active agent, provided that the active agent is not testosterone alone, and that when the active agent is an estrogen or progestin, a therapeutically effective amount of a progestin or estrogen, respectively, is not present in the formulation; and
a delivery vehicle comprising an alkanol, a polyalcohol and a permeation enhancer in an amount sufficient to provide permeation enhancement of the active agent through mammalian dermal or mucosal surfaces;
wherein the formulation is substantially free of long-chain fatty alcohols, long-chain fatty acids and long-chain fatty esters to avoid undesirable odor and irritation from such compounds during use of the formulation. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
-
-
13. A method for treating hormonal disorders in a subject, the method comprising administering to a subject in need of such treatment a formulation comprising a therapeutically effective dosage of at least one active agent and a delivery vehicle comprising an alkanol, a polyalcohol and a permeation enhancer in an amount sufficient to provide permeation enhancement of the active agent through mammalian dermal or mucosal surfaces;
- wherein the hormonal disorder is selected from the group consisting of hypogonadism, female menopausal symptoms, female sexual dysfunction, hypoactive sexual desire disorder, and adrenal insufficiency, and wherein the administration of the formulation decreases the frequency of at least one clinical symptom of the hormonal disorder.
- View Dependent Claims (14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)
-
34. A method for treating hormonal disorders in a subject, the method comprising administering to a subject in need of such treatment a formulation comprising at least one active agent, provided that the active agent is not testosterone alone, and that when the active agent is an estrogen or progestin, a therapeutically effective amount of a progestin or estrogen, respectively, is not present in the formulation, and a delivery vehicle comprising an alkanol, a polyalcohol, and a permeation enhancer in an amount sufficient to provide permeation enhancement of the active agent through dermal or mucosal surfaces;
- wherein the formulation is substantially free of long-chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters to avoid undesirable odor and irritation from such compounds during use of the formulation.
- View Dependent Claims (35, 36)
-
37. A formulation for the transdermal or transmucosal administration of an active agent comprising:
-
at least one active agent; and
a delivery vehicle comprising an alkanol, a polyalcohol and a permeation enhancer of a tetraglycol furol in an amount sufficient to provide permeation enhancement of the active agent through mammalian dermal or mucosal surfaces. - View Dependent Claims (38, 39, 40, 41, 42, 43, 44, 45, 46, 47)
-
- 48. A method for treating hormonal disorders in a subject, the method comprising administering to a subject in need of such treatment a formulation comprising at least one active agent and a delivery vehicle comprising an alkanol, a polyalcohol, and a permeation enhancer of a tetraglycol furol in an amount sufficient to provide permeation enhancement of the active agent through dermal or mucosal surfaces.
-
56. A kit for treating a subject for increasing serum levels of an active agent in a subject comprising:
- a formulation comprising an effective dosage of at least one active agent and a delivery vehicle comprising an alkanol, a polyalcohol and a permeation enhancer in an amount sufficient to provide permeation enhancement of the active agent through mammalian dermal or mucosal surfaces, wherein the formulation is substantially free of long-chain fatty alcohols, long-chain fatty acids and long-chain fatty esters to avoid undesirable odor and irritation from such compounds during use of the formulation; and
a container that retains the formulation and includes a dispenser for releasing or applying a predetermined dosage or volume of the formulation upon demand. - View Dependent Claims (57, 58)
- a formulation comprising an effective dosage of at least one active agent and a delivery vehicle comprising an alkanol, a polyalcohol and a permeation enhancer in an amount sufficient to provide permeation enhancement of the active agent through mammalian dermal or mucosal surfaces, wherein the formulation is substantially free of long-chain fatty alcohols, long-chain fatty acids and long-chain fatty esters to avoid undesirable odor and irritation from such compounds during use of the formulation; and
-
59. A formulation for the transdermal or transmucosal administration of an active agent comprising:
-
at least one active agent comprising dehydroepiandrosterone (DHEA); and
a delivery vehicle comprising an alkanol, a polyalcohol and a permeation enhancer in an amount sufficient to provide permeation enhancement of the active agent through mammalian dermal or mucosal surfaces.
-
Specification